Bronchial Asthma
Conditions
Keywords
bronchial asthma, Traditional Chinese Medicine
Brief summary
Clinical exploring study of Weiyang Yuping Decoction in preventing acute attacks of mild to moderate intermittent asthma Based on the theory of Preventing disease from exacerbating in Chinese medicine.
Detailed description
Based on the preliminary clinical and basic research, this project intends to highly optimize and integrate the TCM treatment of disease theory with the current methods to form two preventive treatment plans, one treatment group was given Weiyang Yupingfang Granules orally for 1 month on the Sanfudays and on the Sanjiu days each year for a total of 2 months one year; the other treatment group was given Weiyang Yupingfang Granules orally for 1 month in the first month of each quarter in the four quarters of the year, for a total of 4 months one year.; Comparing the effect of prevention and treatment of mild to moderate intermittent asthma exacerbations of the two prevention methods , provides new ideas for the prevention and treatment of bronchial asthma in the future, and further improves bronchial The level of prevention and treatment of asthma.
Interventions
DRUGWeiyang Yuping Fang
Weiyang Yuping fang is a combination of the classic ancient Yuping dispersion used to prevent qi deficiency and susceptibility and Bushen Naqi granules optimized formated by Professor Shao Changrong's experience in treating chronic cough and asthma.
Sponsors
Shanghai University of Traditional Chinese Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Intervention model description
One group was given Weiyang Yupingfang Granules orally for 1 month on the Sanfudays and on the Sanjiu days each year for a total of 2 months one year; the other group was given Weiyang Yupingfang Granules orally for 1 month in the first month of each quarter in the four quarters of the year, for a total of 4 months one year.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of asthma according to GINA criteria with a documented history of at least 3 years prior to Visit 1 * Patients have asthma exacerbations every year * Meet the diagnostic criteria for mild to moderate asthma * Able to measure lung ventilation function according to ATS (American Thoracic Society) standards * Patients who have given written informed consent
Exclusion criteria
* Medical history of life-threatening asthma including intubation and intensive care unit admission * Any significant disease or disorder (e.g., cardiovascular, pulmonary other than asthma, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate in the study * Pregnancy, breast-feeding or planned pregnancy during the study. * Participation in another clinical study or took other research drugs during the last 30 days prior to Visit 1 * Known or suspected hypersensitivity to study drugs or excipient * Suspected poor capability, as judged by the investigator, of following instructions of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Annual severe asthma exacerbation rate | up to 12 months after treatment | Measured the change from Baseline of annual severe asthma exacerbation rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to first severe asthma exacerbation | up to 12 months after treatment | Record the time of the patient's first severe asthma exacerbation after treatment |
| Average change from baseline in pre-dose FEV1 | up to 24 months | Measured the change from Baseline of forced expiratory volume in the first second |
| Average change from baseline in pre-dose PEF | up to 24 months | Measured the change from Baseline of peak expiratory flow |
| Average change from baseline in Asthma Control Questionnaire | up to 12 months after treatment | Measured the change from Baseline of Asthma Control Questionnaire (5-item version) - ACQ-5 score |
Countries
China
Outcome results
None listed